10900 results for 'Other Insulin and Insulin-like Receptor Products'

Understanding the EGFR Pathway and YAP in Non-Small Cell Lung CancerThe epidermal growth factor receptor (EGFR) pathway plays a pivotal role in the development and progression of non-small cell lung c

What You Need to Know About PolatuzumabWhat is Polatuzumab??Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, a component of the B-cell receptor, used primarily in B-cel

Vascular Endothelial Growth Factor A (VEGFA) is a pivotal signaling protein involved in both vasculogenesis and angiogenesis, processes essential for the formation of blood vessels during embryoni

Quick Facts About LacnotuzumabWhat is Lacnotuzumab?Lacnotuzumab is a monoclonal antibody targeting CD47, a protein that helps cancer cells evade immune system destruction.What is the mec

Quick Facts About AtezolizumabWhat is Atezolizumab?Atezolizumab is an anti-PD-L1 monoclonal antibody used in immunotherapy to treat various cancers by enhancing the immune system's abili

Almost any inflammatory phenotype in a mouse can be assigned to a cytokine by taking that cytokine away. Neutralisation is the most direct causal test immunology has: inject a functional-grade antibo

Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu

Quick Facts About BelimumabWhat is Belimumab?Belimumab is a monoclonal antibody used to treat systemic lupus erythematosus (SLE), an autoimmune disease. It is marketed under the brand na

In most solid tumours the largest immune population is not a T cell. It is a myeloid cell that has been recruited, expanded and re-educated by the tumour itself. Tumour-associated macrophages and mye

T cells are central players in adaptive immunity, responsible for recognizing and eliminating infected or aberrant cells. Upon encountering antigens, T cells undergo clonal expansion and differ

A T cell does not choose which tissue to defend. The tissue chose it, during priming. A naive T cell has no tropism at all; it acquires one from the dendritic cell that activates it, and the instruct

Quick Facts About UliledlimabWhat is Uliledlimab?Uliledlimab is a monoclonal antibody targeting CD47, a checkpoint protein that helps tumors evade immune system detection. By blocking CD

Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance

For years, our understanding of cancer focused primarily on the tumor cells themselves and the immune system's response. However, a groundbreaking wave of research is revealing a startling truth: ner

If your knockout showed a type 2 phenotype and you attributed it to Th2 cells, there is a reasonable chance you were looking at something else. Innate lymphoid cells run T-bet, GATA3 and RORγt — not

Most immunology is written as though a T cell must first be told what to look for. Three lineages did not read that memo. γδ T cells, invariant NKT cells and MAIT cells leave the thymus with their ef

Quick Facts About CarlumabWhat is Carlumab?Carlumab is a monoclonal antibody developed to target CC-chemokine ligand 2 (CCL2), a key mediator in inflammatory diseases and cancer progress

Antibodies, or immunoglobulins, stand as critical components of the immune system, orchestrating the identification and neutralization of pathogens like viruses and bacteria. This extensive artic

Quick Info Section: Key Facts About PlozalizumabWhat is Plozalizumab?Plozalizumab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint in cancer cells. By

Regulatory T cells cannot make the cytokine they depend on. FOXP3 represses the Il2 locus, so every Treg lives on IL-2 secreted by the conventional T cells it exists to restrain. That asymmetry expla

Block one receptor and more than 90% of the microglia in a mouse brain are dead within a week. Not impaired — gone. Stop the block and they come back, repopulating from the survivors within another w

Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne

Key Facts About EtigilimabWhat is Etigilimab?Etigilimab is an anti-TIGIT monoclonal antibody being studied for its potential role in cancer immunotherapy.What role does Etigilimab play i

Quick Facts About RelatlimabWhat is Relatlimab?Relatlimab is a monoclonal antibody that targets LAG-3 (Lymphocyte Activation Gene-3), a key immune checkpoint involved in T-cell regulatio

Neuroscience · NeuroimmunologyMicroglial Functions: Immunity, Inflammation & NeurodegenerationMicroglia are the resident immune cells of the central nervous system — dynamic sentinels that survey the

Biologics · TNF InhibitionAdalimumab: Mechanism, Clinical Applications and BiosimilarsAdalimumab is a fully human IgG1 monoclonal antibody that binds tumour necrosis factor alpha and prevents it engag

Immune evasion is one of the hallmarks of cancer, where tumor cells employ various strategies to suppress immune responses and prevent destruction by the body’s defense systems. CD200, a

Quick Facts About TesnatilimabWhat is Tesnatilimab?Tesnatilimab is an anti-CD47 monoclonal antibody designed to block the "don’t eat me" signal used by cancer cells to evade immune respo

Key Facts About EnoblituzumabWhat is Enoblituzumab?Enoblituzumab is a monoclonal antibody targeting the B7-H3 protein, which is expressed on the surface of various cancer cells, includin

The most abundant immunosuppressive molecule in a solid tumour is not a protein. It is adenosine — a metabolite, produced from ATP in two enzymatic steps, at concentrations orders of magnitude above

Cancer immunotherapy has revolutionized oncology, offering powerful new ways to treat various malignancies by harnessing the body's own immune system. Central to this success are immune checkpoint inh

V-domain Ig suppressor of T cell activation (VISTA) is an emerging immune checkpoint receptor that plays a key role in suppressing T cell activity within the tumor microenvironment (TME).

Quick Facts About LitifilimabWhat is Litifilimab?Litifilimab is a monoclonal antibody developed by Biogen targeting BDCA2, a receptor on plasmacytoid dendritic cells (pDCs), to regulate

Both interferon families run through STAT1, and that single shared subunit is why they are so often conflated — and why conflating them is a mistake. Type I interferon assembles STAT1 into a three-pa

Immunology Guide 5 Types of Immunoglobulins: IgG, IgA, IgM, IgD & IgE The five antibody classes that drive immune defence — their structure, fun

Quick Facts About EnokizumabWhat is Enokizumab?Enokizumab is a monoclonal antibody designed to target interleukin-9 (IL-9), a cytokine involved in inflammatory responses. It has been stu

Imagine a specialized squad of immune cells, meticulously trained and equipped, not just to fight cancer, but to sniff it out by its unique metabolic scent. This isn't science fiction; it's the groun

For decades, cancer drug development has focused on blocking proteins—inhibiting enzymes, antagonizing receptors, disrupting signaling pathways. Yet this approach leaves a vast landscape of disease-d

A New Era in Oncology Chimeric Antigen Receptor (CAR)-T cell therapy represents a paradigm shift in the fight against cancer, offering a personalized and powerful immunotherapy that trains a patient

Bone Biology · BiomarkersBone Resorption: Process, Markers & Clinical SignificanceBone resorption is the process by which osteoclasts break down bone tissue and release its stored minerals into the bl

IntroductionCancer cells have developed sophisticated mechanisms to evade the immune system, particularly through the inhibition of T-cell responses. One such mechanism involves the progr

Anti-angiogenic therapy does not work by starving tumours, and the trials that assumed it did are the reason the field spent a decade disappointed. Cutting off the blood supply was the original pitch

In the periphery, co-stimulation rescues a T cell. In the thymus, the same molecules kill it. A peripheral T cell that engages its receptor without CD80 and CD86 becomes anergic; engage them and it r

Quick Facts About UlocuplumabWhat is Ulocuplumab?Ulocuplumab is an investigational monoclonal antibody targeting CXCR4, a chemokine receptor involved in tumor progression and immune cell

1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive compon

Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther

Quick Facts About EnfortumabWhat is Enfortumab Vedotin?Enfortumab vedotin is an innovative cancer therapy, primarily used in treating urothelial carcinoma (bladder cancer) that has not r

Key Facts About TalacotuzumabWhat is Talacotuzumab?Talacotuzumab is a monoclonal antibody designed to target CD123, a protein commonly found on the surface of certain blood cancer cells.

What You Need to Know About InebilizumabWhat is Inebilizumab?Inebilizumab is a humanized monoclonal antibody that targets CD19, a protein expressed on B cells, to treat autoimmune diseas

Cell-Based ELISA Kits | 1,600+ Total & Phospho Targets | Assay Genie

PD-1 does not switch a T cell off; it moves the threshold. Engagement of PD-1 by PD-L1 recruits a single phosphatase into the immunological synapse, and that one recruitment event is enough to collap